Variation in the Types of Providers Participating in Breast Cancer Follow-Up Care: A SEER-Medicare Analysis

Ann Surg Oncol. 2017 Mar;24(3):683-691. doi: 10.1245/s10434-016-5611-7. Epub 2016 Oct 5.

Abstract

Background: The current guidelines do not delineate the types of providers that should participate in early breast cancer follow-up care (within 3 years after completion of treatment). This study aimed to describe the types of providers participating in early follow-up care of older breast cancer survivors and to identify factors associated with receipt of follow-up care from different types of providers.

Methods: Stages 1-3 breast cancer survivors treated from 2000 to 2007 were identified in the Surveillance, Epidemiology and End results Medicare database (n = 44,306). Oncologist (including medical, radiation, and surgical) follow-up and primary care visits were defined using Medicare specialty provider codes and linked American Medical Association (AMA) Masterfile. The types of providers involved in follow-up care were summarized. Stepped regression models identified factors associated with receipt of medical oncology follow-up care and factors associated with receipt of medical oncology care alone versus combination oncology follow-up care.

Results: Oncology follow-up care was provided for 80 % of the patients: 80 % with a medical oncologist, 46 % with a surgeon, and 39 % with a radiation oncologist after radiation treatment. The patients with larger tumor size, positive axillary nodes, estrogen receptor (ER)-positive status, and chemotherapy treatment were more likely to have medical oncology follow-up care than older patients with higher Charlson comorbidity scores who were not receiving axillary care. The only factor associated with increased likelihood of follow-up care with a combination of oncology providers was regular primary care visits (>2 visits/year).

Conclusions: Substantial variation exists in the types of providers that participate in breast cancer follow-up care. Improved guidance for the types of providers involved and delineation of providers' responsibilities during follow-up care could lead to improved efficiency and quality of care.

MeSH terms

  • Aftercare / statistics & numerical data*
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Comorbidity
  • Female
  • Humans
  • Lymphatic Metastasis
  • Medical Oncology / statistics & numerical data*
  • Medicare / statistics & numerical data
  • Neoplasm Staging
  • Office Visits / statistics & numerical data
  • Primary Health Care / statistics & numerical data*
  • Radiation Oncology / statistics & numerical data*
  • Receptors, Estrogen / metabolism
  • SEER Program
  • Surgical Oncology / statistics & numerical data*
  • Time Factors
  • Tumor Burden
  • United States

Substances

  • Antineoplastic Agents
  • Receptors, Estrogen